Seeking Alpha

Haemonetics (HAE -8.4%) slides after reporting a mixed FQ3, beating on the bottom line but...

Haemonetics (HAE -8.4%) slides after reporting a mixed FQ3, beating on the bottom line but coming up short on top line revenue. Total sales increased by 19% Y/Y, with organic revenue growth of 11% in Asia and 2% in Europe. which were partially offset by declines of 1% in North America and 2% in Japan. The company reaffirms its outlook for FY13, expecting an EPS of $1.65 - $1.70 on revenues of $888M - $898M,  below the Street view for an EPS of $1.70 on revenues of $900M.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|